E. Yu. Prudnikova

E. Yu. Prudnikova

Auto-generated profile, based on publicly available information

E. Yu. Prudnikova

State Scientific Center of Virology and Biotechnology «Vector

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2023 in Biological Products. Prevention, Diagnosis, Treatment
Verified
Journal Article
Open access
PDF file
VEV. A. Evseenko
V. A. Evseenko
АЗАнна Владимировна Зайковская
Анна Владимировна Зайковская
AGAndrey Gudymo
Andrey Gudymo
OTOleg Taranov
Oleg Taranov
СОС. Е. Олькин
С. Е. Олькин
ARAlexander B Ryzhikov
Alexander B Ryzhikov
Scientific relevance. The use of recombinant antigens in vaccine production is limited because vaccines based on such antigens tend to have low immunogenicity. However, a COVID-19 vaccine that combines recombinant SARS-CoV-2 spike glycoprotein as its antigen and virus-like immune-stimulating complexes (ISCOMs) as its adjuvant (Nuvaxovid) induces a protective virus-neutralising response. The State Research Center of Virology and Biotechnology “Vector” (hereinafter, Vector) has developed the ISCOM adjuvant Matrix-V, which plays a key role in inducing virus-neutralising antibodies. Studying Matrix-V will provide for the wide use of recombinant antigens combined with this adjuvant in the development and production of novel Russian vaccines.Aim. This study aimed to evaluate the humoral immune responses of experimental animals to intramuscular injections of a complex combining the recombinant Wuhan-type SARS-CoV-2 spike RBD antigen and the virus-like ISCOM adjuvant containing Quillaja saponaria saponins.Materials and methods. The Matrix-V ISCOM adjuvant was produced using Vector’s proprietary technology, which involves cross-flow filtration through Sartorius VivaFlow cassettes. To determine the saponin and residual detergent concentrations in Matrix-V, the authors conducted high-performance liquid chromatography. Having produced the recombinant SARS-CoV-2 RBD antigen, the authors used electron microscopy to analyse the ultrastructure of the ISCOM–antigen complex. In the study of the ISCOM–antigen complex, 25 female Balb/c mice (5 groups) and 15 male and female outbred guinea pigs (3 groups) received two intramuscular injections with a 14-day interval. Serum tests relied on virus neutralisation (VN) and enzyme-linked immunosorbent assay (ELISA) methods and used antigens of 8 SARS-CoV-2 variants (State Collection of Viruses and Rickettsia, Vector). The authors used Statistica 10 to analyse the results.Results. Two injections of the SARS-CoV-2 RBD antigen (mice: 7 μg, guinea pigs: 1 μg) alone did not induce statistically significant virus-neutralising antibody responses, as shown by the VN results. Two injections of the SARS-CoV-2 RBD antigen (mice: 7 μg, guinea pigs: 1 μg) adjuvanted with Matrix-V (25 μg) resulted in geometric mean antibody titres of 1:83–1:178 (mice) and 1:174–1:587 (guinea pigs) in the VN tests with the Wuhan variant. One injection of the antigen (1 μg or 7 μg) with Matrix-V (25 μg) induced antibodies only in individual cases, as demonstrated by the VN and/or ELISA results. The most intensive immune response was observed in ELISA tests with the Delta variant after two injections of the Ecto-S-Wuhan (1 μg) and Matrix-V (25 μg) complex. Immune responses did not differ between the group that received two injections of the Ecto-S-Wuhan antigen (1 μg) without the ISCOM adjuvant and the negative control group (titres below 1:100; p=0.95). Two injections of the SARS-CoV-2 RBD antigen (7 μg) without the ISCOM adjuvant induced antibodies in mice (titres between 1:248 and 1:1477).Conclusions. Two intramuscular injections of the complex containing the recombinant SARS-CoV-2 RBD antigen and the Matrix-V ISCOM adjuvant induce virus-neutralising antibodies. The approach proposed by the authors has the potential for use in the development of immunobiological medicinal products to prevent and treat a wide range of infectious diseases.

1 January 2016 in Pharmacy & Pharmacology
Verified
Journal Article
Open access
PDF file
EPE. Yu. Prudnikova
E. Yu. Prudnikova
GPG. N. Poroshin
G. N. Poroshin
NKN. K. Kudina
N. K. Kudina
ILI. V. Lyagoskin
I. V. Lyagoskin
ESE. V. Sazonova
E. V. Sazonova
SAS. G. Abbasova
S. G. Abbasova
Разработка и валидация метода оценки специфической антигемолитической активности препарата экулизумаб (Солирис )

25 March 2020 in Biological Products. Prevention, Diagnosis, Treatment
Verified
Journal Article
Open access
ILIvan Lyagoskin
Ivan Lyagoskin
MPM. S. Pantyushenko
M. S. Pantyushenko
OSOlga Strizhakova
Olga Strizhakova
NKN. K. Kudina
N. K. Kudina
EPE. Yu. Prudnikova
E. Yu. Prudnikova
SAS. G. Abbasova
S. G. Abbasova
Enzyme replacement therapy (ERT) is one of the most efficient treatments for lysosomal storage diseases. Type 1 Gaucher disease is caused by β-glucocerebrosidase enzyme deficiency, which may be compensated for by intravenous infusions of imiglucerase—a recombinant enzyme. Imiglucerase targets macrophages and enters these cells via interaction with mannose receptors on the cell membrane. Characterisation of internalization of enzymes by target cells is important in the context of the development of new medicines and production of existing ERT medicines. The peritoneal and alveolar macrophages, as well as macrophages of the spleen of small laboratory animals (rats and mice) are widely used in such studies. However, isolation of cells from animal sources raises ethical issues, and therefore continuous mammalian cell lines may offer an attractive alternative.The aim of thestudy:to conduct comparative studies on the internalization of recombinant imiglucerase into mouse peritoneal macrophages and L929 mouse fibroblasts.Materials and methods:CerezymeR batches 7HV0913, C6214H05, 7HV0888 (Genzyme Ltd., UK); Glurazim batches 020416, 011117, 021117 (LLC “IBC “Generium”, Russia). We used peritoneal macrophages obtained from BALB/c mice and L929 mouse fibroblasts. The cells were cultured in DMEM/F12 complete growth medium with 10% fetal bovine serum. The activity of imiglucerase internalized into the cells was evaluated spectrophotometrically by hydrolysis of the artificial substrate—4-methylumbelliferyl-β-Dglucopyranoside.Results:the study compared internalization of recombinant imiglucerase (the active ingredient of CerezymeR and Glurazim) by mouse peritoneal macrophages and L929 mouse fibroblasts. It was demonstrated that the medicines activity in the lysates of peritoneal macrophages is comparable with that in the lysates of L929 mouse fibroblasts. Regardless of the model system, the activity of Glurazim stayed within the acceptable range (80–125%) established for biosimilar products.Conclusions:the experiments proved that L929 mouse fibroblasts could be recommended for assessment of internalization of recombinant imiglucerase.

29 December 2025 in Molecular Genetics Microbiology and Virology (Russian version)
Verified
Journal Article
Closed access
TATimur Aliev
Timur Aliev
EPE.YU. Prudnikova
E.YU. Prudnikova
AIAlmaz Ramisovich Imatdinov
Almaz Ramisovich Imatdinov
IIIlnaz Ramisovich Imatdinov
Ilnaz Ramisovich Imatdinov
Objective. New advances in genomic editing field have led to the creation of DNA base editors. Such a tool allows to make precise changes to the genome without double-stranded DNA breaks, which reduces its mutagenicity. As a result, DNA base editors are becoming a popular tool for gene therapy and transgenesis of cell lines and laboratory animals. Of course, there is a need not only to evaluate the effectiveness of editing, but also to create new forms of DNA base editors through evolution. The purpose of our work is to create system to evaluate the effectiveness of DNA base editors and their evolution to obtain new forms. Materials and methods. Classical methods of genetic engineering were used in the work. The proportion of cells with the target effect was assessed by flow cytometry. Results. It is shown that the created systems simulate transgene expression depending on the state of its start-codons. It was revealed that editing of the first start-codon plays a key role in the initiation of translation or its inhibition. Conclusion. Based on the developed systems, it is possible to evaluate the effectiveness of editing the first start-codon of the HIV-1 gag gene and the evolution of DNA base editors to obtain new forms.

7 April 2025 in Problems of Particularly Dangerous Infections
Verified
Journal Article
Open access
PDF file
ATA. E. Tishin
A. E. Tishin
SPS. A. P’yAnkov
S. A. P’yAnkov
EPE. Yu. Prudnikova
E. Yu. Prudnikova
IIIlnaz Ramisovich Imatdinov
Ilnaz Ramisovich Imatdinov
Puumala virus (Orthohantavirus puumalaense) is one of the causative agents of hemorrhagic fever with renal syndrome (HFRS), which is widespread in the Russian Federation (RF): more than 6 thousand cases of HFRS infection are registered annually, over the past decade (2013–2023) – more than 77 thousand cases of the disease were reported. Puumala virus causes up to 98 % of HFRS cases. The development of rapid and highly accurate diagnostic methods, including serological test systems, is of great importance in clinical and laboratory studies aimed at controlling viral infections. The aim of the work was to obtain a recombinant viral immunodominant protein, the nucleoprotein (N), of the Puumala virus, and to study its antigenic properties. Materials and methods. Expression constructs were produced using standard molecular-biological methods. The recombinant nucleoprotein of the Puumala virus was purified in two rounds of metal-chelate affinity chromatography. The antigenic properties of the purified recombinant protein were confirmed by Western blotting and enzyme immunoassay using monoclonal antibodies and convalescent blood sera. Results and discussion. Within the frames of this work, prokaryotic producers have been generated for the production and chromatographic purification of the recombinant nucleoprotein N of the Puumala virus. Using Western blotting and enzyme immunoassay, specific antigenic properties of the recombinant chromatographically purified Puumala virus N protein have been confirmed. Two consecutive rounds of metal-chelate affinity chromatography allowed us to obtain a highly purified recombinant viral protein preparation. The results demonstrate the antigenic specificity of the recombinant chromatographically purified Puumala virus proteins. The preparations can be used to develop serological test systems, including for differentiating vaccinated people from those who have recovered.

1 December 2025 in Molecular Genetics, Microbiology and Virology
Verified
Journal Article
Closed access
TATimur Aliev
Timur Aliev
EPE. Yu. Prudnikova
E. Yu. Prudnikova
AIAlmaz Ramisovich Imatdinov
Almaz Ramisovich Imatdinov
IIIlnaz Ramisovich Imatdinov
Ilnaz Ramisovich Imatdinov